» Articles » PMID: 15155659

Specific in Vivo Deletion of B-cell Subpopulations Expressing Human Immunoglobulins by the B-cell Superantigen Protein L

Overview
Journal Infect Immun
Date 2004 May 25
PMID 15155659
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Some pathogens have evolved to produce proteins, called B-cell superantigens, that can interact with human immunoglobulin variable regions, independently of the combining site, and activate B lymphocytes that express the target immunoglobulins. However, the in vivo consequences of these interactions on human B-cell numbers and function are largely unknown. Using transgenic mice expressing fully human immunoglobulins, we studied the consequences of in vivo exposure of protein L of Peptostreptococcus magnus with human immunoglobulins. In the mature pool of B cells, protein L exposure resulted in a specific reduction of splenic marginal-zone B cells and peritoneal B-1 cells. Splenic B cells exhibited a skewed light-chain repertoire consistent with the capacity of protein L to bind specific kappa gene products. Remarkably, these two B-cell subsets are implicated in innate B-cell immunity, allowing rapid clearance of pathogens. Thus, the present study reveals a novel mechanism that may be used by some infectious agents to subvert a first line of the host's immune defense.

Citing Articles

The Retropepsin-Type Protease APRc as a Novel Ig-Binding Protein and Moonlighting Immune Evasion Factor of .

Curto P, Barro A, Almeida C, Vieira-Pires R, Simoes I mBio. 2021; 12(6):e0305921.

PMID: 34872352 PMC: 8649778. DOI: 10.1128/mBio.03059-21.


A B-Cell Superantigen Induces the Apoptosis of Murine and Human Malignant B Cells.

Lorenzo D, Duarte A, Mundinano J, Berguer P, Nepomnaschy I, Piazzon I PLoS One. 2016; 11(9):e0162456.

PMID: 27603942 PMC: 5014328. DOI: 10.1371/journal.pone.0162456.


Antibody light chain variable domains and their biophysically improved versions for human immunotherapy.

Kim D, To R, Kandalaft H, Ding W, van Faassen H, Luo Y MAbs. 2014; 6(1):219-35.

PMID: 24423624 PMC: 3929445. DOI: 10.4161/mabs.26844.


In vivo VL-targeted microbial superantigen induced global shifts in the B cell repertoire.

Gronwall C, Kosakovsky Pond S, Young J, Silverman G J Immunol. 2012; 189(2):850-9.

PMID: 22696444 PMC: 3598568. DOI: 10.4049/jimmunol.1200245.


Marginal zone B-cells, a gatekeeper of innate immunity.

Zouali M, Richard Y Front Immunol. 2012; 2:63.

PMID: 22566852 PMC: 3341996. DOI: 10.3389/fimmu.2011.00063.


References
1.
Martin F, Kearney J . B-cell subsets and the mature preimmune repertoire. Marginal zone and B1 B cells as part of a "natural immune memory". Immunol Rev. 2000; 175:70-9. View

2.
Cariappa A, Liou H, Horwitz B, Pillai S . Nuclear factor kappa B is required for the development of marginal zone B lymphocytes. J Exp Med. 2000; 192(8):1175-82. PMC: 2195875. DOI: 10.1084/jem.192.8.1175. View

3.
Hardy R, Wasserman R, Li Y, Shinton S, Hayakawa K . Response by B cell precursors to pre-B receptor assembly: differences between fetal liver and bone marrow. Curr Top Microbiol Immunol. 2000; 252:25-30. DOI: 10.1007/978-3-642-57284-5_3. View

4.
Graille M, Stura E, Housden N, Beckingham J, Bottomley S, Beale D . Complex between Peptostreptococcus magnus protein L and a human antibody reveals structural convergence in the interaction modes of Fab binding proteins. Structure. 2001; 9(8):679-87. DOI: 10.1016/s0969-2126(01)00630-x. View

5.
Samardzic T, Marinkovic D, Danzer C, Gerlach J, Nitschke L, Wirth T . Reduction of marginal zone B cells in CD22-deficient mice. Eur J Immunol. 2002; 32(2):561-7. DOI: 10.1002/1521-4141(200202)32:2<561::AID-IMMU561>3.0.CO;2-H. View